DOCSLIB.ORG

Aberrant Gene Expression: Diagnostic Markers and Therapeutic Targets for Pancreatic Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aberrant Gene Expression: Diagnostic Markers and Therapeutic Targets for Pancreatic Cancer ABERRANT GENE EXPRESSION: DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS FOR PANCREATIC CANCER Jeran Kent Stratford A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmacology. Chapel Hill 2014 Approved by: Jen Jen Yeh Channing J. Der Gary L. Johnson Adrienne D. Cox Timothy C. Elston © 2014 Jeran Kent Stratford ALL RIGHTS RESERVED ii ABSTRACT Jeran Kent Stratford: Aberrant gene expression: diagnostic markers and therapeutic targets for pancreatic cancer (Under the direction of Jen Jen Yeh and Channing J. Der) Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer and the fourth leading cause of cancer-related death in the United States. The overall median survival for patients diagnosed with PDAC is five to eight months. The poor outcome is due, in part, to a lack of disease-specific symptoms that can be used for early detection, and as such, most patients present with locally advanced or metastatic disease at the time of diagnosis. Therefore, the need for diagnostic tools is both great and urgent. Furthermore, current chemotherapies have low response rates and high toxicity, limiting their use, and there are currently no effective targeted therapies for PDAC. Therefore, a greater understanding of the underlying biology of pancreatic cancer is needed to identify tumor-specific vulnerabilities that can be therapeutically exploited. Pancreatic cancer development is driven by genomic changes that alter gene expression. Aberrant gene expression produces changes in protein expression, which in turn may confer growth advantages to the tumor; often the tumor then develops a dependency on continued aberrant gene and protein expression. Determining how aberrant genome-wide gene expression changes affect the biology of the tumor is of paramount importance in our continued efforts to improve patient therapy. By identifying and establishing a role for the overexpressed genes in PDAC we can discover new avenues for therapeutic intervention and iii potentially predict the most effective therapy for each individual and avoid therapies that may have little clinical efficacy. My research aimed to identify aberrantly expressed genes in primary tumor samples from PDAC patients and characterize the diagnostic and therapeutic value of the identified genes. The work outlined in this dissertation focuses first on identifying a prognostic signature of genes with the ability to stratify patients into high and low risk groups, and second on assessing the biological importance of overexpression of the dual-specificity protein kinase TTK for pancreatic cancer oncogenesis. Together these two investigations provide a basis for translating molecular changes in tumor biology into improved therapy for pancreatic cancer patients. iv To Mindy, my ever steady companion v ACKNOWLEDGEMENTS First I wish to thank my mentors, Jen Jen Yeh and Channing Der. I sincerely thank you for all of the encouragement and time you have spent on my behalf as advisors. It was only through your continued support and guidance that the work contained in this dissertation was made possible. Your combined knowledge has aided me in discovering how to apply basic research to key clinical questions, one of the main goals I wanted to accomplish in my graduate career. I appreciate the patience and guidance I have received from both of you as I have struggled through developing experimental methods and the ever-daunting process of writing. I will always appreciate the sacrifices you have made on my behalf to mold me into the scientist I have become. Secondly I wish to thank the Department of Pharmacology for all of the support I have received. I would not have been able to accomplish this work had I not been fortunate enough to collaborate with such exceptional faculty and students. This has been such a unique opportunity to learn and grow as a scientist and as a person. In addition I would like to thank the members of the Yeh and Der labs both past and present. Thank you for helping guide me through the hard times and share in the joy of the good times. Lastly, I thank my wonderful and ever-growing family. Family is forever and I appreciate your patience and interest in me as I have pursued this doctorate. I’d like to thank my father and mother for their encouragement and support even though I moved over 2000 miles away from them. Thank you for your positive outlook and well-timed packages of vi candy. Finally, a thank you to Mindy, my sweet wife. This would have been impossible had I not had you by my side. You have provided me with the strength I didn’t have on my own to stay the course through your amazing example and kind words. You’re simply the best. I love you and can never say thank you enough. vii TABLE OF CONTENTS LIST OF TABLES .................................................................................................................. X LIST OF FIGURES .............................................................................................................. XI LIST OF ABBREVIATIONS ............................................................................................ XII CHAPTERS I. INTRODUCTION ........................................................................................................ 1 PANCREAS ANATOMY AND FUNCTION ........................................................................... 2 PANCREATIC DUCTAL ADENOCARCINOMA DEVELOPMENT ............................................ 2 STAGING OF PANCREATIC CANCER ................................................................................ 5 PANCREATIC DUCTAL ADENOCARCINOMA OUTCOME AND TREATMENT ........................ 9 GENOMIC INSTABILITY ................................................................................................ 14 SPINDLE ASSEMBLY CHECKPOINT ................................................................................ 14 TTK ............................................................................................................................ 16 APC/C ........................................................................................................................ 18 GENETICS OF PANCREATIC DUCTAL ADENOCARCINOMA .............................................. 23 GENE EXPRESSION PROFILING ..................................................................................... 27 SUMMARY ................................................................................................................... 29 viii II. A SIX-GENE SIGNATURE PREDICTS SURVIVAL OF PATIENTS WITH LOCALIZED PANCREATIC DUCTAL ADENOCARCINOMA .......................... 32 OVERVIEW .................................................................................................................. 32 INTRODUCTION ............................................................................................................ 33 EXPERIMENTAL PROCEDURES ...................................................................................... 34 RESULTS ..................................................................................................................... 39 DISCUSSION ................................................................................................................ 48 III. GENETIC AND PHARMACOLOGIC INHIBITION OF TTK IMPAIRS PANCREATIC CANCER CELL LINE GROWTH BY INDUCING LETHAL LEVELS OF CHROMOSOMAL INSTABILITY .................................................... 54 OVERVIEW .................................................................................................................. 54 INTRODUCTION ............................................................................................................ 55 EXPERIMENTAL PROCEDURES ...................................................................................... 58 RESULTS ..................................................................................................................... 64 DISCUSSION ................................................................................................................ 84 IV. CONCLUSIONS AND FUTURE DIRECTIONS ..................................................... 90 DIAGNOSTIC GENE EXPRESSION FOR PANCREATIC DUCTAL ADENOCARCINOMA .......... 90 GENE EXPRESSION SIGNATURES AND SUBTYPES OF DISEASE ....................................... 91 THERAPEUTIC VALUE OF TTK FOR PANCREATIC DUCTAL ADENOCARCINOMA ............. 92 TTK PHOSPHORYLATION SUBSTRATES ........................................................................ 95 USP16 SUBSTRATES AND REGULATION ........................................................................ 96 SUMMARY ................................................................................................................... 97 REFERENCES ........................................................................................................................ 98 ix LIST OF TABLES Table 1. Pancreatic cancer TNM classification ........................................................................... 6 Table 2. AJCC stage groupings for pancreatic cancer ................................................................ 7 Table 3. ECOG Performance Status ........................................................................................... 15 Table 4. Patient, tumor, and treatment characteristics in the derivation set ................................ 40 Table 5. Patient, tumor, and treatment characteristics
Load more

Recommended publications
  • By Submitted in Partial Satisfaction of the Requirements for Degree of in In
    Developments of Two Imaging based Technologies for Cell Biology Researches by Xiaowei Yan DISSERTATION Submitted in partial satisfaction of the requirements for degree of DOCTOR OF PHILOSOPHY in Biochemistry and Molecular Biology in the GRADUATE DIVISION of the UNIVERSITY OF CALIFORNIA, SAN FRANCISCO Approved: ______________________________________________________________________________Ronald Vale Chair ______________________________________________________________________________Jonathan Weissman ______________________________________________________________________________Orion Weiner ______________________________________________________________________________ ______________________________________________________________________________ Committee Members Copyright 2021 By Xiaowei Yan ii DEDICATION Everything happens for the best. To my family, who supported me with all their love. iii ACKNOWLEDGEMENTS The greatest joy of my PhD has been joining UCSF, working and learning with such a fantastic group of scientists. I am extremely grateful for all the support and mentorship I received and would like to thank: My mentor, Ron Vale, who is such a great and generous person. Thank you for showing me that science is so much fun and thank you for always giving me the freedom in pursuing my interest. I am grateful for all the guidance from you and thank you for always supporting me whenever I needed. You are a person full of wisdom, and I have been learning so much from you and your attitude to science, science community and even life will continue inspire me. Thank you for being my mentor and thank you for being such a great mentor. Everyone else in Vale lab, past and present, for making our lab a sweet home. I would like to give my special thank to Marvin (Marvin Tanenbaum) and Nico (Nico Stuurman), two other mentors for me in the lab. I would like to thank them for helping me adapt to our lab, for all the valuable advice and for all the happiness during the time that we work together.
    [Show full text]
  • SERS and MD Simulation Studies of a Kinase Inhibitor Demonstrate the Emergence of a Potential Drug Discovery Tool
    SERS and MD simulation studies of a kinase inhibitor demonstrate the emergence of a potential drug discovery tool Dhanasekaran Karthigeyana,1, Soumik Siddhantab,1, Annavarapu Hari Kishorec,1, Sathya S. R. R. Perumald, Hans Ågrend, Surabhi Sudevana, Akshay V. Bhata, Karanam Balasubramanyama, Rangappa Kanchugarakoppal Subbegowdac,2, Tapas K. Kundua,2, and Chandrabhas Narayanab,2 aTranscription and Disease Laboratory, Molecular Biology and Genetics Unit, bLight Scattering Laboratory, Chemistry and Physics of Materials Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064, India; cDepartment of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore 570006, India; and dDepartment of Theoretical Chemistry and Biology, School of Biotechnology, KTH Royal Institute of Technology, Roslagstullsbacken 15, SE-114 21 Stockholm, Sweden Edited by Michael L. Klein, Temple University, Philadelphia, PA, and approved May 30, 2014 (received for review February 18, 2014) We demonstrate the use of surface-enhanced Raman spectroscopy be screened for therapeutic applications. This paper provides a (SERS) as an excellent tool for identifying the binding site of small prelude to this development. This finding also facilitates the molecules on a therapeutically important protein. As an example, developing field of tip-enhanced Raman spectroscopy for im- we show the specific binding of the common antihypertension aging the small molecule interactions for in vitro and in vivo drug felodipine to the oncogenic Aurora A kinase protein via applications. A completely developed SERS–MD simulation hydrogen bonding interactions with Tyr-212 residue to specifically combination with adequate help from the structure of the pro- inhibit its activity. Based on SERS studies, molecular docking, tein may help converge potential small molecules for therapeutic molecular dynamics simulation, biochemical assays, and point applications and reduce the time for drug discovery.
    [Show full text]
  • USP16 Counteracts Mono-Ubiquitination of Rps27a And
    RESEARCH ARTICLE USP16 counteracts mono-ubiquitination of RPS27a and promotes maturation of the 40S ribosomal subunit Christian Montellese1†, Jasmin van den Heuvel1,2, Caroline Ashiono1, Kerstin Do¨ rner1,2, Andre´ Melnik3‡, Stefanie Jonas1§, Ivo Zemp1, Paola Picotti3, Ludovic C Gillet1, Ulrike Kutay1* 1Institute of Biochemistry, ETH Zurich, Zurich, Switzerland; 2Molecular Life Sciences Ph.D. Program, Zurich, Switzerland; 3Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland Abstract Establishment of translational competence represents a decisive cytoplasmic step in the biogenesis of 40S ribosomal subunits. This involves final 18S rRNA processing and release of residual biogenesis factors, including the protein kinase RIOK1. To identify novel proteins promoting the final maturation of human 40S subunits, we characterized pre-ribosomal subunits trapped on RIOK1 by mass spectrometry, and identified the deubiquitinase USP16 among the captured factors. We demonstrate that USP16 constitutes a component of late cytoplasmic pre-40S subunits that promotes the removal of ubiquitin from an internal lysine of ribosomal protein *For correspondence: RPS27a/eS31. USP16 deletion leads to late 40S subunit maturation defects, manifesting in [email protected] incomplete processing of 18S rRNA and retarded recycling of late-acting ribosome biogenesis Present address: †CSL Behring, factors, revealing an unexpected contribution of USP16 to the ultimate step of 40S synthesis. CSL Biologics Research Center, Finally, ubiquitination of RPS27a appears to depend on active translation, pointing at a potential ‡ Bern, Switzerland; MSD Merck connection between 40S maturation and protein synthesis. Sharp & Dohme AG, Lucerne, Switzerland; §Institute of Molecular Biology and Biophysics, ETH Zurich, Zurich, Switzerland Introduction Ribosomes stand at the center of translation in all kingdoms of life, catalyzing the synthesis of pro- Competing interests: The teins by reading a messenger RNA (mRNA) template.
    [Show full text]
  • Role of Senataxin in RNA: DNA Hybrids Resolution at DNA Double
    Role of senataxin in RNA : DNA hybrids resolution at DNA double strand breaks Sarah Cohen To cite this version: Sarah Cohen. Role of senataxin in RNA : DNA hybrids resolution at DNA double strand breaks. Cellular Biology. Université Paul Sabatier - Toulouse III, 2019. English. NNT : 2019TOU30125. tel-02930730 HAL Id: tel-02930730 https://tel.archives-ouvertes.fr/tel-02930730 Submitted on 4 Sep 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. ����� ���� ������������������ ������������������������������������ ��������� ���!������"������ �� "��#�$�% ��� � ���� %��"���������"� ��� ��� � � � &������ ������������ ������� ����'������"�� � (����� �"�� ���"�� �������"�&)�����"����*���� (�+ "" ��"��� ��������"�����!��� ������������������,�,�$�,����-��.�� ���.�,����+&����-��" �������������,����/�������������� �������������������� �,�0�%�$�� ��� ���������,����-������� � �������0���+ � ����� ������'������� ������'������������ %����1�� ����� ����������������� /��������/�,�� ��� ���������� ������������������� ������������������������������ �� �����������������
    [Show full text]
  • The Ins and Outs of Autophagic Ribosome Turnover
    Biochemistry, Biophysics and Molecular Biology Publications Biochemistry, Biophysics and Molecular Biology 2019 The Ins and Outs of Autophagic Ribosome Turnover Zakayo Kazibwe Iowa State University, [email protected] Ang-Yu Liu Iowa State University, [email protected] Gustavo C. Macintosh Iowa State University, [email protected] Diane C. Bassham Iowa State University, [email protected] Follow this and additional works at: https://lib.dr.iastate.edu/bbmb_ag_pubs Part of the Cell and Developmental Biology Commons, Genetics Commons, and the Molecular Biology Commons The complete bibliographic information for this item can be found at https://lib.dr.iastate.edu/ bbmb_ag_pubs/260. For information on how to cite this item, please visit http://lib.dr.iastate.edu/howtocite.html. This Article is brought to you for free and open access by the Biochemistry, Biophysics and Molecular Biology at Iowa State University Digital Repository. It has been accepted for inclusion in Biochemistry, Biophysics and Molecular Biology Publications by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. The Ins and Outs of Autophagic Ribosome Turnover Abstract Ribosomes are essential for protein synthesis in all organisms and their biogenesis and number are tightly controlled to maintain homeostasis in changing environmental conditions. While ribosome assembly and quality control mechanisms have been extensively studied, our understanding of ribosome degradation is limited. In yeast or animal cells, ribosomes are degraded after transfer into the vacuole or lysosome by ribophagy or nonselective autophagy, and ribosomal RNA can also be transferred directly across the lysosomal membrane by RNautophagy. In plants, ribosomal RNA is degraded by the vacuolar T2 ribonuclease RNS2 after transport by autophagy-related mechanisms, although it is unknown if a selective ribophagy pathway exists in plants.
    [Show full text]
  • Stem Cell Modulators
    Stem Cell Modulators Reprogramming Self-Renewal Differentiation Cancer Stem Cells LKT Laboratories | lktlabs.com Biochemicals for Life Science Research Biochemicals for Life Science Research | lktlabs.com Influencing Stem Cell Biology with Small Molecules Small molecules are playing an of target proteins at precise points in increasingly important role in the time. Their synthesis routes are well advancement of stem cell research and developed and the compounds are well technology. They are versatile tools characterized, meaning that they are that have shown effectiveness in ev- high in purity and low in variability erything from somatic cell reprogram- between batches, both key factors in ming to stem cell renewal to differen- reproducibility. They are cost-effective tiation of pluripotent stem cells. They relative to growth factors, and they are have increased the efficiency and speed safer than using viral vectors that can at which cells move to and from plu- introduce unwanted genetic material. ripotency, unlocking new avenues of Small molecules are playing an integral previously cost-prohibitive research. In role in improving our understanding some cases, small molecules have even of stem cells, and enabling advance- helped somatic cells bypass the need to ments in stem cell technology. move to pluripotency altogether in a process called transdifferentiation. As stem cell research tools, small molecules offer a variety of inher- ent benefits. They offer a high degree of control to researchers, as they are able to reversibly alter the function Reprogramming Somatic Cells With Small Molecules ID Name Class Description Purity A001001 A 83-01 TGF-β inhibitor Enables Oct4-induced reprogramming in mouse fibroblasts.
    [Show full text]
  • Ohnologs in the Human Genome Are Dosage Balanced and Frequently Associated with Disease
    Ohnologs in the human genome are dosage balanced and frequently associated with disease Takashi Makino1 and Aoife McLysaght2 Smurfit Institute of Genetics, University of Dublin, Trinity College, Dublin 2, Ireland Edited by Michael Freeling, University of California, Berkeley, CA, and approved April 9, 2010 (received for review December 21, 2009) About 30% of protein-coding genes in the human genome are been duplicated by WGD, subsequent loss of individual genes related through two whole genome duplication (WGD) events. would result in a dosage imbalance due to insufficient gene Although WGD is often credited with great evolutionary impor- product, thus leading to biased retention of dosage-balanced tance, the processes governing the retention of these genes and ohnologs. In fact, evidence for preferential retention of dosage- their biological significance remain unclear. One increasingly pop- balanced genes after WGD is accumulating (4, 7, 11–20). Copy ular hypothesis is that dosage balance constraints are a major number variation [copy number polymorphism (CNV)] describes determinant of duplicate gene retention. We test this hypothesis population level polymorphism of small segmental duplications and show that WGD-duplicated genes (ohnologs) have rarely and is known to directly correlate with gene expression levels (21– experienced subsequent small-scale duplication (SSD) and are also 24). Thus, CNV of dosage-balanced genes is also expected to be refractory to copy number variation (CNV) in human populations deleterious. This model predicts that retained ohnologs should be and are thus likely to be sensitive to relative quantities (i.e., they are enriched for dosage-balanced genes that are resistant to sub- dosage-balanced).
    [Show full text]
  • Inhibiting USP16 Rescues Stem Cell Aging and Memory in An
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.383059; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Title: Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model Authors: Felicia Reinitz1†, Elizabeth Chen1†, Benedetta Nicolis di Robilant1†, Bayarsaikhan Chuluun2, Jane Antony1, Robert C. Jones3, Neha Gubbi1, Sai Saroja Kolluru3, Dalong Qian1, Katja Piltti4, Aileen Anderson4, Michelle Monje1, H. Craig Heller2, Stephen Quake3, Michael F. Clarke1* Affiliations: 1Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California 94305, USA. 2Department of Biology, Stanford University School of Medicine, Stanford, California 94305, USA. 3Bioengineering, Stanford University School of Engineering and Medicine, Stanford, California, 94305, USA. 4Sue and Bill Gross Stem Cell Research Center, University of California, Irvine *Lead contact and all other correspondence to: [email protected] †These authors contributed equally. 1 Summary: Alzheimer’s disease (AD) is a progressive neurodegenerative disease observed with 2 aging that represents the most common form of dementia. To date, therapies targeting end-stage 3 disease plaques, tangles, or inflammation have limited efficacy. Therefore, we set out to identify 4 an earlier targetable phenotype. Utilizing a mouse model of AD and human fetal cells harboring 5 mutant amyloid precursor protein, we show cell intrinsic neural precursor cell (NPC) dysfunction 6 precedes widespread inflammation and amyloid plaque pathology, making it the earliest defect in 7 the evolution of disease.
    [Show full text]
  • 伊域化學藥業（香港）有限公司 Cyclohexanes
    ® 伊域化學藥業（香港）有限公司 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD Rm 1006, 10/F, Hewlett Centre, Tel: (852) 25412772 (4 lines) No. 52-54, Hoi Yuen Road, Fax: (852) 25423444 / 25420530 / 21912858 Kwun Tong, E-mail: [email protected] YICK -VIC 伊域 Kowloon, Hong Kong. Site: http://www.yickvic.com Cyclohexanes Product Code CAS Product Name PH-4912ML 147730-52-7 (-)-ISOLOLIOLIDE PH-4912MA 5989-02-6 (-)-LOLIOLIDE 11028-27-6 PH-4912MJ 38274-00-9 (+)-ISOLOLIOLIDE PH-4912MC 81444-64-6 (+)-LOLIOLIDE UNIE-2649 (+/-)-1,3-CYCLOHEXANEDICARBOXYLIC ACID PH-4912MN 93497-68-8 (+/-)-ISOLOLIOLIDE PH-4912ME 10481-90-0 (+/-)-LOLIOLIDE SPI-3169AB 1121-22-8 (+/-)-TRANS-1,2-DIAMINOCYCLOHEXANE MIS-23027 943515-16-0 (1-(2-BENZYLOXYETHYL)-4-(TERT-BUTYLDIMETHYLSILANYLOXY)CYCLOHEXYL)METHANOL MIS-7408 482-54-2 (1,2-CYCLOHEXYLENEDINITRILO)TETRAACETIC ACID MIS-14439 944537-61-5 (13BR)-5,6-DIHYDRO-5-(TRANS-4-PROPYLCYCLOHEXYL)-4H-DINAPHTHO[2,1-F:1',2'-H][1,5]DIOXONIN MIS-17938 76784-95-7 (1ALPHA,2ALPHA,4ALPHA)-1,2,4-CYCLOHEXANETRICARBOXYLIC ACID MIS-17939 16526-68-4 (1ALPHA,3ALPHA,5ALPHA)-1,3,5-CYCLOHEXANETRICARBOXYLIC ACID MIS-14124 14602-86-9 (1R)-(-)-MENTHYL CHLOROFORMATE MIS-16932 167416-28-6 (1R)-1-(DICYCLOHEXYLPHOSPHINO)-2-[(1R)-1-(DICYCLOHEXYLPHOSPHINO)ETHYL]FERROCENE Copyright © 2016 YICK-VIC CHEMICALS & PHARMACEUTICALS (HK) LTD. All rights reserved. Page 1 of 43 Product Code CAS Product Name MIS-16930 292638-88-1 (1R)-1-[BIS[3,5-BIS(TRIFLUOROMETHYL)PHENYL]PHOSPHINO]-2-[(1R)-1-(DICYCLOHEXYLPHOSPHINO)ETHYL]FERROCENE SPI-3169AG 191480-63-4 (1R,2R)-(-)-1,2-CYCLOHEXANEDIAMINE
    [Show full text]
  • Morphology, Behavior, and the Sonic Hedgehog Pathway in Mouse Models of Down Syndrome
    MORPHOLOGY, BEHAVIOR, AND THE SONIC HEDGEHOG PATHWAY IN MOUSE MODELS OF DOWN SYNDROME by Tara Dutka A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland July, 2014 © 2014 Tara Dutka All Rights Reserved Abstract Down Syndrome (DS) is caused by a triplication of human chromosome 21 (Hsa21). Ts65Dn, a mouse model of DS, contains a freely segregating extra chromosome consisting of the distal portion of mouse chromosome 16 (Mmu16), a region orthologous to part of Hsa21, and a non-Hsa21 orthologous region of mouse chromosome 17. All individuals with DS display some level of craniofacial dysmorphology, brain structural and functional changes, and cognitive impairment. Ts65Dn recapitulates these features of DS and aspects of each of these traits have been linked in Ts65Dn to a reduced response to Sonic Hedgehog (SHH) in trisomic cells. Dp(16)1Yey is a new mouse model of DS which has a direct duplication of the entire Hsa21 orthologous region of Mmu16. Dp(16)1Yey’s creators found similar behavioral deficits to those seen in Ts65Dn. We performed a quantitative investigation of the skull and brain of Dp(16)1Yey as compared to Ts65Dn and found that DS-like changes to brain and craniofacial morphology were similar in both models. Our results validate examination of the genetic basis for these phenotypes in Dp(16)1Yey mice and the genetic links for these phenotypes previously found in Ts65Dn , i.e., reduced response to SHH. Further, we hypothesized that if all trisomic cells show a reduced response to SHH, then up-regulation of the SHH pathway might ameliorate multiple phenotypes.
    [Show full text]
  • Centrifugal Recovery of Embryonic Stem Cells for Regenerative Medicine Bioprocessing
    Centrifugal recovery of embryonic stem cells for regenerative medicine bioprocessing Ju Wei Wong Department of Biochemical Engineering University College London A thesis submitted for the degree of Doctor of Philosophy September 2008 To my parents Poh Poh and Judy For their love, unconditional support and untold sacrifices and without whom, none of this would have been possible. Acknowledgements It is a pleasure to thank the many people who made this thesis an en- joyable experience. First and foremost, I would like to express my thanks and gratitude to Professor Mike Hoare for his invaluable support, guidance and encour- agement throughout the course of my graduate studies. He has been instrumental in fostering a culture of intellectual challenge, rigour and discovery. He taught me how to ask questions and express my ideas. He showed me different ways to approach a research problem and the need to be patient, yet persistent and open to accomplish my goals. I would also like to thank my advisor Professor Chris Mason for his scientific knowledge, advice and providing insightful discussions and suggestions for my research. A number of colleagues and fellow graduate students have played some kind of role in my research and time here at UCL. In this regard, I am indebted to Diana for her idiot proof masterclasses in stem cell biology and laboratory techniques, Emily, Spyros, Simon, Alex, Ioannis, Charo and especially Alfred, Minal and Emma for making tea, coffee and things interesting, and also for their immeasurable perspective on laboratory and result related issues. I would also like to take this opportunity to thank Julia Markusen who together with Chris, encouraged me to apply for graduate school.
    [Show full text]
  • A Systematic Genome-Wide Association Analysis for Inflammatory Bowel Diseases (IBD)
    A systematic genome-wide association analysis for inflammatory bowel diseases (IBD) Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Christian-Albrechts-Universität zu Kiel vorgelegt von Dipl.-Biol. ANDRE FRANKE Kiel, im September 2006 Referent: Prof. Dr. Dr. h.c. Thomas C.G. Bosch Koreferent: Prof. Dr. Stefan Schreiber Tag der mündlichen Prüfung: Zum Druck genehmigt: der Dekan “After great pain a formal feeling comes.” (Emily Dickinson) To my wife and family ii Table of contents Abbreviations, units, symbols, and acronyms . vi List of figures . xiii List of tables . .xv 1 Introduction . .1 1.1 Inflammatory bowel diseases, a complex disorder . 1 1.1.1 Pathogenesis and pathophysiology. .2 1.2 Genetics basis of inflammatory bowel diseases . 6 1.2.1 Genetic evidence from family and twin studies . .6 1.2.2 Single nucleotide polymorphisms (SNPs) . .7 1.2.3 Linkage studies . .8 1.2.4 Association studies . 10 1.2.5 Known susceptibility genes . 12 1.2.5.1 CARD15. .12 1.2.5.2 CARD4. .15 1.2.5.3 TNF-α . .15 1.2.5.4 5q31 haplotype . .16 1.2.5.5 DLG5 . .17 1.2.5.6 TNFSF15 . .18 1.2.5.7 HLA/MHC on chromosome 6 . .19 1.2.5.8 Other proposed IBD susceptibility genes . .20 1.2.6 Animal models. 21 1.3 Aims of this study . 23 2 Methods . .24 2.1 Laboratory information management system (LIMS) . 24 2.2 Recruitment. 25 2.3 Sample preparation. 27 2.3.1 DNA extraction from blood. 27 2.3.2 Plate design .
    [Show full text]